Table of Contents
ISRN Hematology
Volume 2013, Article ID 673781, 5 pages
Research Article

Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed

1Liv Ulus Hospital, Department of Gastroenterohepatology, 34347 Istanbul, Turkey
2Istanbul Education and Research Hospital, Department of Internal Diseases, 34098 Istanbul, Turkey
3Bezmialem University Medical Faculty, Department of Haematology, 34093 Istanbul, Turkey
4Istanbul Education and Research Hospital, Department of Haematology, 34098 Istanbul, Turkey
5Istanbul Education and Research Hospital, Department of Radiology, 34098 Istanbul, Turkey
6Istanbul Education and Research Hospital, Department of Gastroenterohepatology, 34098 Istanbul, Turkey

Received 16 July 2013; Accepted 16 August 2013

Academic Editors: E. Abruzzese and F. Passamonti

Copyright © 2013 Ahmet Burak Toros et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background/Objectives. Patients with myeloproliferative neoplasms have a well-established increased risk of thrombosis. Many trials report identification of an underlying myeloproliferative neoplasm by investigation of the patients developing portal hypertensive esophagus and/or fundus variceal hemorrhage in the absence of any known etiology. This trial was designed to investigate the association between myeloproliferative neoplasms and portal hypertension and to detect the frequency of portal hypertension development in this subset of patients. Methodology. Twenty-nine patients previously diagnosed with polycythemia vera, essential thrombocytopenia, and primary myelofibrosis, who were under followup at the hematology outpatient clinic of our hospital, were included in the trial. Results. In our trial, we detected portal hypertension in 13.8% of the patients ( ), as a finding that was similar to those obtained in other studies performed to date. Conclusions. Considering the fact that diagnosis of myeloproliferative neoplasms usually takes a long time, treatment should be started (while, on the other hand, assessing the investigational and therapeutical choices for the complications) right after the bone marrow biopsy or cytogenetic studies required for establishing the final diagnosis have been performed.